Celcuity Inc. (CELC)

Market Cap	447.20M
Revenue (ttm)	n/a
Net Income (ttm)	-127.16M
Shares Out	37.87M
EPS (ttm)	-3.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,249
Open	11.80
Previous Close	11.78
Day's Range	11.68 - 12.39
52-Week Range	7.58 - 19.77
Beta	0.39
Analysts	Strong Buy
Price Target	30.80 (+160.8%)
Earnings Date	Aug 13, 2025

About CELC

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 87
• Stock Exchange: NASDAQ
• Ticker Symbol: CELC
• Website: https://www.celcuity.com

Analyst Forecast

According to 5 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price forecast is $30.8, which is an increase of 160.80% from the latest price.

Price Target

$30.8

(160.80% upside)

Analyst Consensus: Strong Buy